|
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma …
Business Wire (press release) SAN ANTONIO, Texas–(BUSINESS WIRE)–Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS†/LABA‡, irrespective … Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News